Integra LifeSciences Holdings (NASDAQ:IART) — Market Cap & Net Worth
Market Cap & Net Worth: Integra LifeSciences Holdings (IART)
Integra LifeSciences Holdings (NASDAQ:IART) has a market capitalization of $1.18 Billion ($1.18 Billion) as of September 21, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8235 globally and #2403 in its home market, demonstrating a -2.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Integra LifeSciences Holdings's stock price $15.22 by its total outstanding shares 77796903 (77.80 Million). Also see Integra LifeSciences Holdings (IART) total assets for a full breakdown of the balance sheet.
Integra LifeSciences Holdings Market Cap History: 2015 to 2026
Integra LifeSciences Holdings's market capitalization history from 2015 to 2026. Data shows change from $2.64 Billion to $1.18 Billion (-6.16% CAGR). Also see cash efficiency ratio of Integra LifeSciences Holdings for how efficiently the company converts equity into cash flow.
Index Memberships
Integra LifeSciences Holdings is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.65 Trillion | 0.04% | #238 of 976 |
|
NASDAQ Composite
IXIC
|
$42.12 Trillion | 0.00% | #893 of 3165 |
|
S&P Small-Cap 600 Index
SML
|
$1.61 Trillion | 0.10% | #432 of 602 |
Weight: Integra LifeSciences Holdings's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Integra LifeSciences Holdings Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Integra LifeSciences Holdings's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Integra LifeSciences Holdings stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.59x
Integra LifeSciences Holdings's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.34 Billion | $992.08 Million | $74.56 Million | 3.36x | 44.75x |
| 2017 | $3.72 Billion | $1.19 Billion | $64.74 Million | 3.13x | 57.51x |
| 2018 | $3.51 Billion | $1.47 Billion | $60.80 Million | 2.38x | 57.71x |
| 2019 | $4.53 Billion | $1.52 Billion | $50.20 Million | 2.99x | 90.32x |
| 2020 | $5.05 Billion | $1.37 Billion | $133.89 Million | 3.68x | 37.72x |
| 2021 | $5.21 Billion | $1.54 Billion | $169.07 Million | 3.38x | 30.82x |
| 2022 | $4.36 Billion | $1.56 Billion | $180.55 Million | 2.80x | 24.16x |
| 2023 | $3.39 Billion | $1.54 Billion | $67.74 Million | 2.20x | 50.01x |
| 2024 | $1.76 Billion | $1.61 Billion | -$6.94 Million | 1.10x | N/A |
| 2025 | $966.24 Million | $1.64 Billion | -$516.47 Million | 0.59x | N/A |
Competitor Companies of IART by Market Capitalization
Companies near Integra LifeSciences Holdings in the global market cap rankings as of September 21, 2026. Review how tangible is Integra LifeSciences Holdings's equity to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Integra LifeSciences Holdings by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #124 globally with a market cap of $178.43 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #238 globally with a market cap of $105.53 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #240 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #124 | Abbott Laboratories | NYSE:ABT | $178.43 Billion | $102.61 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.13 |
| #238 | Stryker Corporation | NYSE:SYK | $105.53 Billion | $275.12 |
| #240 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Integra LifeSciences Holdings Historical Marketcap From 2015 to 2026
Between 2015 and today, Integra LifeSciences Holdings's market cap moved from $2.64 Billion to $ 1.18 Billion, with a yearly change of -6.16%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.18 Billion | +22.54% |
| 2025 | $966.24 Million | -45.24% |
| 2024 | $1.76 Billion | -47.92% |
| 2023 | $3.39 Billion | -22.33% |
| 2022 | $4.36 Billion | -16.30% |
| 2021 | $5.21 Billion | +3.19% |
| 2020 | $5.05 Billion | +11.39% |
| 2019 | $4.53 Billion | +29.22% |
| 2018 | $3.51 Billion | -5.77% |
| 2017 | $3.72 Billion | +11.57% |
| 2016 | $3.34 Billion | +26.57% |
| 2015 | $2.64 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Integra LifeSciences Holdings was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.18 Billion USD |
| MoneyControl | $1.18 Billion USD |
| MarketWatch | $1.18 Billion USD |
| marketcap.company | $1.18 Billion USD |
| Reuters | $1.18 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Integra LifeSciences Holdings
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural … Read more